Mar 08, 2023 / 02:50PM GMT
Jayson Tyler Bedford - Raymond James & Associates, Inc., Research Division - MD & Senior Medical Supplies and Devices Analyst
All right. Good morning. I think we'll start. Welcome to the third day of the Raymond James Institutional Investors Conference. We certainly appreciate the packed house on the third day with the sun shining out there. So we appreciate that. Thank you. I'm Jayson Bedford. I cover the medical technology sector here at Raymond James. And it's really our pleasure to have with us Tandem Diabetes for the first time at this conference, I think.
So we have the company's CFO, Leigh Vosseller, and we have the company's CEO, John Sheridan, who will walk through the story.
John F. Sheridan - Tandem Diabetes Care, Inc. - President, CEO & Director
Thanks, Jayson. It's nice to be here. Am I on? Okay, very nice see this morning. I think what I'd like to do is just kind of give you an overview of Tandem, where we're going, what the markets look like, our pipeline. And just give you a good sense of what you can expect from us over the
Tandem Diabetes Care Inc at Raymond James Institutional Investors Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot